Last updated: August 26, 2026
Methscopolamine bromide is an established, low-volume oral anticholinergic with limited apparent patent protection and a narrow commercial base. The strongest opportunity is a low-cost, reliable immediate-release tablet using a conservative excipient system, supported by manufacturing quality, supply continuity, and regulatory execution rather than novel-molecule exclusivity.
What is methscopolamine bromide and how is it used?
Methscopolamine bromide is a quaternary ammonium antimuscarinic agent supplied as an oral tablet. It has been used as an adjunct in the treatment of peptic ulcer disease and hypersecretory gastrointestinal conditions, although modern acid-suppression therapies have reduced its clinical importance.
| Attribute |
Methscopolamine bromide |
| Active ingredient |
Methscopolamine bromide |
| Pharmacologic class |
Quaternary ammonium anticholinergic |
| Common strengths |
2.5 mg and 5 mg tablets |
| Dosage form |
Immediate-release oral tablet |
| Prescription status |
Prescription product |
| Primary historical use |
Adjunctive treatment for peptic ulcer and gastrointestinal hypersecretion |
| Administration |
Oral |
| Major safety considerations |
Dry mouth, blurred vision, constipation, urinary retention, tachycardia, reduced sweating |
| Biosimilar pathway |
Not applicable |
| Primary U.S. regulatory route for competition |
ANDA, subject to reference-product and Orange Book status |
The quaternary ammonium structure limits central nervous system penetration compared with tertiary amine anticholinergics. The drug still carries clinically relevant peripheral anticholinergic risks, particularly in older adults and patients with glaucoma, urinary retention, gastrointestinal obstruction, or tachyarrhythmias. The FDA labeling identifies these risks and limits the product’s broad-market potential. (U.S. Food and Drug Administration [FDA], n.d.-a)
What excipients are used in methscopolamine bromide tablets?
Publicly available product labels identify conventional tablet excipients, including lactose, starch-based disintegrants, magnesium stearate, and other standard processing aids. Exact qualitative and quantitative compositions vary by manufacturer and product presentation. The reference product and current generic products should be compared through their FDA labeling, DailyMed entries, and, where available, inactive-ingredient records. (National Library of Medicine, n.d.)
A commercially practical immediate-release formulation would normally use the following functional architecture:
| Formulation function |
Candidate excipient classes |
Commercial purpose |
| Diluent |
Lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate |
Provides tablet mass and improves manufacturability |
| Binder |
Pregelatinized starch, povidone, hydroxypropyl cellulose |
Supports granule and tablet strength |
| Disintegrant |
Sodium starch glycolate, crospovidone, croscarmellose sodium |
Promotes rapid tablet breakup |
| Glidant |
Colloidal silicon dioxide |
Improves powder flow |
| Lubricant |
Magnesium stearate, sodium stearyl fumarate |
Reduces sticking and ejection force |
| Film coating |
Hypromellose, polyethylene glycol, titanium dioxide, colorants |
Improves swallowability, appearance, and product identification |
Because the dose is low, content uniformity is more important than tablet-size reduction. A 2.5 mg tablet can create blend-uniformity and segregation risks if the active is not adequately dispersed. A formulation that performs well at 5 mg may not scale directly to the lower strength.
What is the best excipient strategy for methscopolamine bromide?
The preferred strategy is a simple, robust immediate-release platform with minimal excipient switching between strengths. Direct compression may be viable if the active has acceptable flow and blend uniformity. Wet granulation is more defensible when the low dose, poor flow, or segregation risk makes direct compression unreliable.
Direct-compression strategy
A direct-compression formulation could combine microcrystalline cellulose or lactose with a superdisintegrant, colloidal silicon dioxide, and magnesium stearate. The approach offers:
- Fewer processing steps
- Lower manufacturing cost
- Reduced exposure to water and heat
- Easier scale-up across contract manufacturing sites
- Shorter development timelines
The key risks are active segregation, lubricant sensitivity, and weight variation. These risks are material for a low-dose tablet and should be managed through controlled particle-size distribution, geometric dilution, validated blending, and in-process content-uniformity testing.
Wet-granulation strategy
Wet granulation can improve blend uniformity and reduce segregation. It is more suitable when the active has poor flow or when direct compression produces unacceptable tablet variability. The principal disadvantages are higher cost, longer processing time, and potential drug-excipient or drug-moisture interactions.
Methscopolamine bromide is a salt and should be assessed for moisture sensitivity, hygroscopicity, and stability under granulation conditions. The process should avoid unnecessary water exposure unless stability data support an aqueous granulation route.
Film-coating strategy
A thin hypromellose-based coating can support product differentiation without changing the drug-release profile. Coating may improve:
- Swallowability
- Tablet identification
- Moisture protection
- Patient acceptance
- Packaging and handling performance
The coating should not become the primary commercial differentiator. For a low-demand generic, an opaque, low-weight-gain film coat is generally more economically rational than an elaborate modified-release or taste-masking system.
What formulation patents protect methscopolamine bromide products?
The original product and active ingredient are old. Patent protection for the core molecule and conventional immediate-release tablet technology is expected to have expired. The current commercial issue is therefore regulatory and manufacturing execution rather than basic composition-of-matter exclusivity.
Potentially relevant intellectual-property categories include:
| IP category |
Likely current relevance |
| Composition-of-matter patents |
Expired or commercially immaterial because of the age of the molecule |
| Conventional immediate-release tablets |
Likely expired or unavailable as a meaningful barrier |
| Specific excipient combinations |
Usually weak unless tied to a novel technical effect |
| Modified-release formulations |
Potentially protectable, but limited by clinical and commercial demand |
| New indications |
Theoretical opportunity, but requires clinical evidence |
| Manufacturing processes |
May be protectable if novel, but difficult to enforce against routine tablet manufacturing |
| Device or packaging patents |
Limited value for a conventional oral tablet |
The commercial review should distinguish between active patents, expired patents, abandoned applications, and patents that are not listed in the FDA Orange Book. A patent number alone does not establish a market barrier.
What is the Orange Book status of methscopolamine bromide?
The FDA Orange Book identifies approved prescription drug products and, where applicable, patents and regulatory exclusivities. Methscopolamine bromide should be reviewed by active ingredient, dosage form, strength, and reference-listed-drug designation. (FDA, n.d.-b)
The likely market profile is:
| Regulatory issue |
Commercial assessment |
| Reference product |
Historical oral methscopolamine bromide tablet product |
| ANDA opportunity |
Potentially available if an eligible reference-listed drug and current product approval exist |
| Orange Book patents |
No obvious active composition patent barrier based on the drug’s age |
| NCE exclusivity |
Expired |
| Orphan exclusivity |
Not a central feature of the product’s historical pathway |
| Pediatric exclusivity |
No material current impact expected |
| 180-day generic exclusivity |
Depends on any qualifying first-filer and current Orange Book activity |
| Paragraph IV risk |
Likely low for a simple legacy product, but must be assessed against any currently listed patents |
An applicant should not assume that historical approval guarantees a currently active ANDA pathway. Product availability, reference-product status, discontinued-drug determinations, and FDA listing history can affect the regulatory strategy. The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations and Drugs@FDA databases are the controlling sources for current U.S. status. (FDA, n.d.-b; FDA, n.d.-c)
When does methscopolamine bromide lose exclusivity?
Methscopolamine bromide lost ordinary small-molecule exclusivity decades ago. The active ingredient was marketed before the modern Hatch-Waxman framework, and any original composition or product patents would generally have expired long before the current market.
| Exclusivity type |
Current assessment |
| Composition patent exclusivity |
Expired |
| New chemical entity exclusivity |
Expired |
| Original product patent protection |
Expired or no longer commercially relevant |
| Method-of-use protection |
No widely recognized current barrier for historical indications |
| Biosimilar exclusivity |
Not applicable |
| Pediatric exclusivity |
No apparent current commercial significance |
| Orphan exclusivity |
No apparent current commercial significance |
The practical question is not when exclusivity ends. It is whether a sponsor can obtain approval and operate profitably in a low-volume market with limited clinical demand.
Are Paragraph IV challenges likely for methscopolamine bromide?
A Paragraph IV certification is relevant only if an ANDA applicant challenges a patent listed for the reference product. For an old immediate-release tablet, the most likely outcome is a Paragraph III certification, a Paragraph IV certification against a residual formulation or use patent, or no listed patent certification if no relevant patent remains.
A Paragraph IV strategy would have limited value unless:
- The Orange Book lists a patent that blocks approval.
- The listed patent has a commercially relevant remaining term.
- The product has enough market value to support litigation.
- The applicant can obtain a meaningful launch advantage from the challenge.
For methscopolamine bromide, litigation economics appear weak compared with high-revenue products. A sponsor would more likely pursue a standard ANDA route than create a litigation-centered launch plan.
What generic entry risks exist for methscopolamine bromide?
Generic entry risk is high in the sense that patent barriers appear limited. Commercial entry risk is also high because demand is likely narrow and incumbent supply may already satisfy much of the market.
| Risk |
Impact |
| Low prescription volume |
Limits revenue and reduces incentive for multiple manufacturers |
| Physician substitution |
May be limited because newer therapies dominate gastrointestinal treatment |
| Product discontinuation |
Creates potential shortages but also signals weak demand |
| API availability |
Low-volume API sourcing may be vulnerable to minimum-order constraints |
| Low-dose content uniformity |
Raises technical and validation risk |
| Reimbursement pressure |
Compresses net price |
| Limited clinical differentiation |
Makes premium pricing difficult |
| Anticholinergic safety concerns |
Restricts use in older and medically complex patients |
A new entrant could gain share if it offers reliable supply, consistent wholesaler availability, and a lower-cost product. A shortage-driven opportunity may exist, but it would be difficult to forecast and should not be treated as a durable franchise.
How strong is the patent estate for methscopolamine bromide?
The patent estate is weak for a conventional oral tablet. The molecule is old, the therapeutic application is established, and the likely formulation components are standard pharmaceutical excipients.
Patent-strength assessment
| Patent dimension |
Strength |
| Core molecule |
Very low |
| Conventional tablet composition |
Very low |
| Immediate-release process |
Low |
| Novel excipient system |
Low to moderate if supported by unexpected stability or bioequivalence benefits |
| Modified release |
Moderate technical potential, but uncertain commercial value |
| New indication |
Potentially moderate, with substantial clinical-development cost |
| Manufacturing route |
Low to moderate, depending on process novelty and enforceability |
| Trade secrets |
Moderate for process controls, supplier qualification, and analytical methods |
A sponsor should prioritize trade secrets and operational know-how over a broad patent program. Useful proprietary assets could include a low-dose blending process, a moisture-controlled packaging system, a high-yield granulation process, or a validated impurity-control strategy. These assets may improve economics even if they do not create a durable legal monopoly.
What commercial opportunities exist for methscopolamine bromide?
The most credible opportunities are niche generic and supply-continuity plays.
1. Reliable generic supply
If the market has intermittent shortages or few active suppliers, a sponsor could compete through:
- Dual API sourcing
- Domestic or regional secondary packaging
- Safety-stock commitments
- Multi-strength manufacturing
- Consistent wholesaler availability
- Small-batch flexibility
This model depends on operating discipline. A low-volume product can be attractive if manufacturing is integrated into an existing oral-solid-dose platform.
2. Contract manufacturing and private-label supply
A manufacturer with existing tablet capacity could add methscopolamine bromide to a portfolio of legacy products. The product may fit an established platform using lactose, starch, a superdisintegrant, and magnesium stearate.
Private-label distribution could target:
- Regional wholesalers
- Long-term-care pharmacies
- Hospital systems
- Specialty generic distributors
- State or federal purchasing programs
3. Reformulation opportunity
A differentiated formulation could target tablet size, swallowability, stability, or packaging. The commercial case for modified release is less clear because it would likely require additional clinical or regulatory work and may not address the core demand problem.
Potential concepts include:
| Concept |
Technical value |
Commercial outlook |
| Smaller tablet |
Better swallowing and lower excipient load |
Moderate |
| Film-coated tablet |
Better handling and identification |
Moderate |
| Moisture-protective blister |
Longer shelf-life and supply resilience |
Moderate |
| Orally disintegrating tablet |
Potential convenience benefit |
Uncertain; taste and anticholinergic adverse effects remain issues |
| Extended-release product |
Reduced dosing frequency |
Potentially meaningful but development-intensive |
| Combination product |
May target a defined indication |
High regulatory and clinical burden |
4. International markets
Geographic opportunities depend on local registration status, treatment guidelines, and the availability of competing anticholinergics. Markets with continued use of older gastrointestinal antispasmodics may offer more demand than the United States, but country-specific regulatory and reimbursement review is essential.
A global strategy would need to address:
- Local monographs and pharmacopeial requirements
- Country-specific approved strengths
- API import controls
- Language and labeling requirements
- Local pharmacovigilance
- Regional reference-product rules
- Price controls and tender purchasing
How does methscopolamine bromide compare with competing anticholinergics?
Methscopolamine bromide competes with both older anticholinergics and modern gastrointestinal therapies. Its quaternary ammonium structure may offer a peripheral-action positioning, but the market is constrained by anticholinergic tolerability and the availability of proton-pump inhibitors, H2-receptor antagonists, and other therapies.
| Product class |
Relative commercial position |
| Methscopolamine bromide |
Legacy, low-volume oral anticholinergic |
| Hyoscyamine |
Broader antispasmodic positioning and multiple dosage forms |
| Glycopyrrolate |
Stronger peripheral-anticholinergic positioning in selected uses |
| Atropine-containing products |
Different clinical and combination-product uses |
| Proton-pump inhibitors |
Dominant acid-suppression alternatives |
| H2 antagonists |
Established alternatives for acid-related disorders |
Methscopolamine is unlikely to win through therapeutic superiority in a broad primary-care market. Its competitive position is more credible as a dependable legacy product for established prescribers and institutional channels.
What manufacturing and IP barriers affect market entry?
The main barriers are technical and economic:
- Demonstrating acceptable blend uniformity at the 2.5 mg strength.
- Controlling assay and content uniformity across commercial batch sizes.
- Establishing dissolution equivalence to the reference product.
- Managing moisture and salt-form stability.
- Securing a qualified low-volume API supplier.
- Achieving acceptable commercial scale at low annual demand.
- Maintaining regulatory compliance despite limited product revenue.
The product may be suitable for a manufacturer that already produces low-dose immediate-release tablets. It is less attractive as a stand-alone development program requiring new facilities, dedicated equipment, or a large sales organization.
What licensing deals or litigation affect methscopolamine bromide?
No major recent licensing transaction, high-value patent settlement, or material Hatch-Waxman litigation is broadly associated with methscopolamine bromide. The product’s age and limited market size reduce the likelihood of a litigation-driven licensing market.
A transaction would more likely involve:
- A portfolio acquisition of legacy generic products
- An ANDA transfer
- Contract manufacturing rights
- Regional commercialization rights
- API supply and finished-dose manufacturing
- A shortage or discontinuation remediation arrangement
Any diligence should verify current FDA approval ownership, discontinued-product status, National Drug Code activity, wholesaler availability, and Orange Book patent listings before assigning value to the asset.
Key Takeaways
- Methscopolamine bromide is a legacy oral anticholinergic with limited current market breadth.
- The core molecule and conventional tablet technology have little apparent remaining patent value.
- The preferred formulation is a simple immediate-release tablet using standard diluents, disintegrants, glidants, lubricants, and optional film coating.
- Low-dose content uniformity is the central technical issue, particularly for the 2.5 mg strength.
- The strongest commercial opportunity is reliable generic supply integrated into an existing oral-solid-dose manufacturing platform.
- Modified-release, orally disintegrating, or combination products could create differentiation but would carry disproportionate development risk.
- Biosimilar risk is irrelevant because methscopolamine bromide is a small molecule.
- Paragraph IV litigation is unlikely to be the primary market-entry strategy.
- Revenue potential is likely limited unless the sponsor captures a shortage, gains a preferred institutional contract, or bundles the product with a larger legacy-generic portfolio.
FAQs
Is methscopolamine bromide still commercially available?
Methscopolamine bromide has appeared in U.S. prescription tablet listings and legacy product records, but current availability can vary by manufacturer, wholesaler, and National Drug Code status. FDA and DailyMed records provide the relevant product-level information. (FDA, n.d.-c; National Library of Medicine, n.d.)
Can methscopolamine bromide be developed as an over-the-counter product?
An over-the-counter switch would require FDA review of safety, labeling, consumer-use conditions, and a suitable nonprescription monograph or application. Anticholinergic risks, including urinary retention, glaucoma-related complications, and tachycardia, would make a switch commercially and regulatorily demanding.
Which excipient is most important for the 2.5 mg tablet?
The most important excipient function is not a single ingredient but uniform distribution of the low-dose active. A well-controlled diluent and binder system, supported by an effective disintegrant and validated blending process, is more important than selecting a novel excipient.
Is an orally disintegrating methscopolamine bromide tablet commercially attractive?
It could improve administration for selected patients, but taste, dose uniformity, moisture sensitivity, packaging, and anticholinergic tolerability would limit the opportunity. The product would need a clear patient-use advantage to justify development costs.
Could a methscopolamine bromide shortage support premium pricing?
A shortage could create temporary pricing leverage, but the opportunity would depend on duration, competing products, FDA shortage records, payer response, and the sponsor’s ability to maintain supply. It should be treated as a contingent supply opportunity rather than a stable premium market.
References
-
National Library of Medicine. (n.d.). DailyMed: Methscopolamine bromide tablet labeling. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.-a). Methscopolamine bromide prescribing information. https://www.accessdata.fda.gov/
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (n.d.-c). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
